16th November 2020
The patent landscape behind the Nobel Prize awarded to CRISPR
CRISPR Nobel Prize Award
The 2020 Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier in October for their work on the gene editing tool CRISPR/Cas 9, commonly referred to as CRISPR.
This Nobel Prize does not come without some controversy. Not only are the winners involved in a patent dispute relating to CRISPR, where Doudna’s and Charpentier’s interests are represented by the University of California while Feng Zhang, on the other side of the patent dispute, is active at The Broad Institute of MIT and Harvard and was notably not included in the award by the Nobel committee.
We have looked into the patents behind the CRISPR technology and discovered who the key players are in this space and how this is impacting the patent landscape.
Our article explores some of the following key findings:
- The potential of CRISPR is undisputed, but who controls the patent assets?
- Although universities are still in control of some of the largest patent portfolios relating to the CRISPR tool, commercial organisations are actively using and patenting this technology.
- DuPont De Nemours and Regeneron Pharmaceuticals have comparatively small portfolios, but they are equally as important to the Harvard, MIT and Broad Institute portfolios.
If you’d like to learn more about how Cipher has enabled this Competitive Intelligence analysis, get in touch contact us directly.
Insights & Events
Ams completes acquisition of Osram
Analog Devices buys Maxim
Banking Cybersecurity webinar
Digital Tokens: who is innovating to ensure safety in payments?
Fintech – Understanding the role of patents
With Cipher you can…
Optimise your portfolio
Ensure you have the right portfolio to meet your strategic patenting objectives.
Gather competitor intelligence
Understand who’s doing what by automating patent to technology mapping.
Model cross licensing
Combine patent and revenue data to determine rational licensing outcomes.
Conduct due diligence
Automate manual reviews for efficient execution of M&A and licensing transactions.
Tackle inbound patent assertion
Be prepared with evidence to create a fast and effective threat assessment.
Benchmark your portfolio
Assess your portfolio in comparison to other owners through your technology lens.
Monetise your portfolio
Identify opportunities to create value through licensing or sale of patent assets.
Predict technology trends
Track new technologies and discover the unknown owners of future innovation.
Create Risk Mitigation Strategies
Understand the materiality of your threats to define your risk mitigation strategy.